Market Place
Sourcing Support
CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study
30 Sep 2022 //
EUROPEANPHARMACEUTICALREVIEW
Bioheng Biotech Announces Publication of Impressive Results CD7-targeted CAR-T
26 Sep 2022 //
BIOSPACE
Bioheng`s CTB001 received ODD from the U.S. FDA
28 Jan 2022 //
PRNEWSWIRE
US FDA grants orphan drug designation to Bioheng Biotech’s CTD401 to treat T-ALL
22 Jun 2021 //
PHARMABIZ
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.